Announcements Trials
Browse Landscape

Phase

Phase 2 1

Status

Active not recruiting 1

Sponsor Class

NETWORK 1

Study Type

Interventional 1

Sponsor

Cancer Type

Endocrine 1

Conditions

Breast Neoplasms 72Colorectal Neoplasms 43Rectal Neoplasms 41Stomach Neoplasms 38Triple Negative Breast Neoplasms 30Neoplasm Metastasis 19Esophageal Neoplasms 16Colonic Neoplasms 16Pancreatic Neoplasms 12Parkinson Disease 4, Autosomal Dominant Lewy Body 11Neoplasms 11Nasopharyngeal Carcinoma 11Adenocarcinoma 11Biliary Tract Neoplasms 10Adenocarcinoma Of Esophagus 9Cholangiocarcinoma 7Locally Advanced Rectal Cancer 6Esophageal Squamous Cell Carcinoma 6Brain Neoplasms 6Anus Neoplasms 6Recurrence 5Gastrointestinal Neoplasms 5Squamous Cell Carcinoma of Head and Neck 4Neuroendocrine Tumors 4HER2-positive Breast Cancer 4Colorectal Cancer Metastatic 4Carcinoma, Non-Small-Cell Lung 4Carcinoma, Hepatocellular 4Pathologic Complete Response 3Ovarian Neoplasms 3

Interventions

Temozolomide 1Capecitabine 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Gastrinoma × Capecitabine × 1 year × Clear all
NCT01824875 2026-02-25

Temozolomide With or Without Capecitabine in Treating Patients With Advanced Pancreatic Neuroendocrine Tumors

Eastern Cooperative Oncology Group

Phase 2 Active not recruiting
144 enrolled 15 charts
Endocrine

Glucagonoma, Insulinoma, Adenoma, Islet Cell, Somatostatinoma, Gastrinoma, Carcinoma, Islet Cell

Data powered by HemOnc (CC BY 4.0) Colophon âš¡